妊娠期意外接种四价HPV疫苗的母婴结局
本研究纳入2007至2014年间17-28岁美国现役军人女性至少一次妊娠及所产婴儿,通过行政医疗记录识别妊娠与结局,免疫记录确定妊娠期4vHPV暴露,采用多变量回归计算风险比及95%CI。结果显示约2%妊娠和婴儿暴露于4vHPV,调整后未发现妊娠期意外暴露与任何不良妊娠或婴儿结局存在正相关。
要点
- 妊娠期意外接种4vHPV未增加自然流产、子痫前期/子痫、早产等不良结局风险。
- 约2%的妊娠和婴儿在妊娠期暴露于4vHPV。
- 4vHPV虽已不在美国使用,但海外仍在接种,安全性研究仍有意义。
核心结论
- 妊娠期意外暴露于4vHPV与不良妊娠或婴儿结局无正相关。
研究设计与样本
- 回顾性队列研究,纳入2007-2014年美国现役军人女性17-28岁至少一次妊娠及所产婴儿,共90,600次妊娠和75,670例单胎婴儿。
主要发现
- 约2%的妊娠和婴儿在妊娠期暴露于4vHPV。
- 调整后未发现妊娠期4vHPV暴露与自然流产、子痫前期/子痫、早产、出生缺陷、婴儿期或宫内生长问题、婴儿性别存在正相关。
临床怎么用
- 可为妊娠期意外接种4vHPV的妇女提供 reassurance,并可能外推至9vHPV(共享四种抗原)的意外暴露。
局限性
- 4vHPV已不在美国使用,但海外仍在接种,安全性研究仍需持续。
- 9vHPV在孕妇中的安全性尚未确立。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The Department of Defense encourages service members ≤26 years of age to receive the human papillomavirus (HPV) vaccine. Although this vaccine is not recommended in pregnancy, inadvertent vaccination may occur. The objective of this study was to assess whether active duty US military women who received the quadrivalent HPV vaccine (4vHPV) during pregnancy were at increased risk for adverse maternal or infant outcomes. METHODS: The study population included active duty US military women aged 17-28 years with at least one pregnancy between 2007 and 2014, and the infants resulting from those pregnancies. Pregnancies, live births, and outcomes were identified using medical codes in administrative medical records. Exposure to 4vHPV during pregnancy was ascertained from personnel immunization records. Multivariable regression models were used to calculate risk estimates and 95% confidence intervals for the maternal outcomes of spontaneous abortion, preeclampsia/eclampsia and preterm labor, and the infant outcomes of preterm birth, birth defects, growth problems in infancy or in utero, and infant sex. RESULTS: Overall, 90,600 pregnancies and 75,670 singleton infants were identified. Approximately 2% of pregnancies and infants were exposed to 4vHPV during pregnancy. After adjustments, no positive associations were detected between inadvertent exposure to 4vHPV during pregnancy and any adverse pregnancy or infant outcomes. DISCUSSION: Our findings add to an established body of literature demonstrating the safety of 4vHPV when inadvertently administered during pregnancy. Although 4vHPV is no longer administered in the US, its use continues overseas; therefore, safety studies remain important. Furthermore, such studies can provide reassurance to women inadvertently exposed to nonavalent HPV vaccine (9vHPV) in pregnancy, which protects against four of the same antigens as 4vHPV, since safety of 9vHPV has not yet been established in pregnant women.
引用
- Bukowinski AT, Hall C, Chang RN, et al. Maternal and infant outcomes following exposure to quadrivalent human papillomavirus vaccine during pregnancy. Vaccine. 2020. PMID: 32712082. doi:10.1016/j.vaccine.2020.06.073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。